Contents
Academy · Research Promotion · Confidentiality & Data Security
Confidentiality in the Preparation of Scientific Content: HIPAA Pathways and Commercial Confidentiality
The Health Insurance Portability and Accountability Act (HIPAA) Privacy Rule sets out specific, named pathways for the use of protected health information in research: Institutional Review Board (IRB) waiver, a limited data set under a data use agreement, or individual authorization. Each pathway carries documented safeguard requirements, which a scientific content project must match to the data it handles.
Confidentiality in scientific content preparation covers two distinct obligations that are often conflated: protecting any patient-level health information the underlying research may contain, and protecting commercially sensitive, pre-publication information such as unpublished data, draft content, or a sponsor's strategic framing before it is intended to be public. The first is governed by specific regulatory frameworks such as HIPAA's Privacy Rule in the United States; the second is governed by confidentiality agreements and internal review controls, but both ultimately rest on the same underlying principle GPP2022 and publication-ethics bodies apply to sponsored content: access to sensitive information should be limited to those with a documented need, and that access should be traceable.
Learning objectives
- The specific pathways HIPAA's Privacy Rule sets out for using protected health information in research
- What a data use agreement under a limited data set requires of the recipient
- How commercial confidentiality before publication connects to the same accountability standard governing sponsored content generally
Common misconceptions
- “Confidentiality in medical content work mostly means not posting the deck publicly before it's approved.” HIPAA's Privacy Rule sets out several specific, named pathways for using protected health information in research, including an IRB or Privacy Board waiver requiring a documented plan to protect and destroy identifiers, and a limited data set released only under a data use agreement obligating the recipient to apply specific safeguards and report any unauthorized use, a far more structured set of obligations than simply controlling who sees a draft file.
Two distinct obligations within confidentiality
When a scientific content project involves patient-level health information, confidentiality means complying with a specific regulatory framework, in the United States, HIPAA's Privacy Rule, governing how that protected health information can be used and disclosed for research purposes7. When a project involves no patient-level data but does involve unpublished research findings, a sponsor's strategic framing, or draft content not yet approved for release, confidentiality instead means limiting access to people with a documented need and tracking who has seen or edited sensitive material, consistent with the access-and-accountability logic GPP2022 and COPE's guidance on medical-communications-company involvement both apply to sponsored content generally15. Treating these as the same obligation leads either to under-protection of patient data or to over-restriction of ordinary draft review; they should be managed as related but distinct requirements.
Research pathways under the HIPAA Privacy Rule
HIPAA's Privacy Rule permits covered entities to use or disclose protected health information for research only through specific, named pathways. An Institutional Review Board or Privacy Board can waive the requirement for individual authorization, but only if it documents that privacy risk is minimal, requiring a plan to protect identifiers from improper use, a plan to destroy them as early as the research allows, and written assurance the information will not be reused or disclosed beyond what is permitted7. A "preparatory to research" pathway allows limited use strictly to prepare a protocol, provided no protected health information leaves the covered entity7. Individual authorization, meeting the specific requirements set out in the regulation, is the most direct pathway and may be combined with informed consent7. Any scientific content project that involves real patient data should identify specifically which of these named pathways applies, rather than assuming that a general confidentiality agreement covers the same ground.
Requirements of a limited data set and data use agreement
A limited data set, which excludes a specified list of direct identifiers, can be used under a data use agreement that is itself a specific, binding document: it must limit permitted uses and who can access the data, and the recipient must agree not to use or disclose the data beyond the agreement's terms, to apply appropriate safeguards, to report any unauthorized use or disclosure, to pass the same restrictions on to any subcontractor, and not to attempt to identify or contact the individuals the data describes7. This is a materially more structured obligation than a general nondisclosure agreement, and a scientific content team working from a limited data set should be able to point to the specific data use agreement governing that data, not simply a project-level confidentiality clause.
Pre-publication commercial confidentiality and its common principle
For the more common case, where a scientific content project involves no patient-level data but does involve unpublished findings or draft content, the underlying principle is the same one GPP2022 and COPE's guidance apply to sponsored content accountability generally: access should be limited to those with a documented need, and every person who had access, and what they contributed, should be traceable15. In practice, this entails version-controlled draft files rather than freely forwarded copies, a documented list of who has reviewed or edited a given draft, and the same disclosure obligations around contributor involvement that the BMJ’s 2005 report on tightened ghost-writing guidance and the ISMPP CMPP Code of Conduct both identify as the standard to which this kind of work is held84. Confidentiality and accountability, in this sense, are two aspects of the same requirement: knowing precisely who had access to sensitive content, and being able to demonstrate it.
Practical safeguards applicable to both forms of confidentiality
A small set of practical safeguards applies to both the HIPAA-governed and the purely commercial aspects of confidentiality in scientific content work, even though the underlying legal basis differs. The first is limiting access on a documented, need-to-know basis rather than through a blanket project-wide share: HIPAA’s limited-data-set pathway requires precisely this kind of restriction by agreement7, and the same restriction, applied to a pre-publication draft, constitutes good practice consistent with GPP2022’s accountability expectations even where no specific regulation requires it1. The second is maintaining a dated access log, recording who viewed or edited a sensitive file and when, since it is this record that makes an access restriction enforceable and auditable rather than a policy that exists only on paper. The third is building a destruction or retention schedule into the project plan from the outset, rather than allowing sensitive files to accumulate indefinitely across shared drives; this mirrors the specific destruction-planning requirement that HIPAA’s IRB waiver pathway imposes for protected health information, and is a reasonable practice to apply to sensitive pre-publication commercial material as well, even where no regulation specifically requires it7. None of these three practices is complicated to implement, but all three must be planned from the start of a project rather than retrofitted once a confidentiality concern has arisen.
A final practical safeguard is to determine, at the outset of any scientific content project, whether the project involves patient-level data at all, since this determination changes which of the safeguards above apply. A project built entirely from already-published, aggregate study results involves no protected health information and therefore falls outside HIPAA’s research pathways entirely, so the relevant obligations are the commercial-confidentiality and disclosure practices described above rather than any HIPAA-specific requirement. Conversely, a project that incorporates patient-level data from a company’s own clinical trial database, even in small or summarized form, requires its HIPAA pathway to be identified explicitly before any content work begins, not discovered partway through the project when a reviewer asks where a specific figure originated. Making this determination explicitly, in writing, at project initiation, rather than leaving it as an implicit assumption, is the single step most likely to prevent a confidentiality obligation from being overlooked entirely.
Organizations operating across multiple countries face an additional layer of complexity: HIPAA is a U.S. framework, and a project involving patient data collected outside the United States may instead fall under a different regime, such as the European Union’s General Data Protection Regulation (GDPR), with its own distinct consent, processing, and cross-border transfer requirements that do not map one-to-one onto HIPAA’s pathways. A scientific content project drawing on data from a multinational clinical trial should identify which jurisdiction’s framework governs each relevant data element, rather than assuming that a single confidentiality approach, built around one country’s regulatory framework, satisfies every jurisdiction the underlying data touch. This is a complex determination in many cases, and it is a further reason why confidentiality planning belongs at the outset of a project, when there is still time to obtain appropriate regulatory guidance, rather than at the point when a deck is nearly finished and a jurisdictional question arises unexpectedly.
A project’s confidentiality obligations should also be revisited periodically across a long engagement rather than confirmed once at initiation and assumed to remain fixed, because scope tends to expand as new data sources or new contributors are added partway through. Each new data source added to an in-progress project should be checked against the same pathway-identification process described above before it is incorporated, rather than assumed to be covered by whatever determination applied to the project’s original, narrower scope.
Key points
Key points
Confidentiality in the preparation of scientific content encompasses two distinct obligations: HIPAA-governed protection of patient-level health information through specific, named pathways, and access and traceability controls over unpublished commercial content. Each project should identify which obligation applies to its data rather than treating a general confidentiality clause as sufficient for both.
Practical application
Practical application
- The applicable HIPAA pathway should be identified before any patient-level data are used. It should be confirmed whether the project relies on an IRB/Privacy Board waiver, a limited data set under a data use agreement, or individual authorization, and that choice should be documented.
- A data use agreement should be treated as a specific, binding document rather than a generic non-disclosure agreement (NDA). The agreement should be confirmed to include the safeguard, non-identification and subcontractor-restriction terms required by the HIPAA limited-data-set pathway.
- A documented access and edit trail should be maintained for unpublished draft content. Version-controlled files and a recorded list of every reviewer or editor should be used, consistent with the accountability standard that GPP2022 applies to sponsored content.
Frequently asked questions
No; HIPAA's Privacy Rule requires one of its specific named pathways, an IRB/Privacy Board waiver, a limited data set under a data use agreement, or individual authorization, each with its own documented requirements that a general confidentiality clause does not automatically satisfy.
A limited data set excludes a specified list of direct identifiers but can still be used only under a data use agreement with binding safeguard and non-identification obligations; fully de-identified data falls outside the Privacy Rule's restrictions entirely because it is not considered protected health information.
It is generally a contractual and internal-governance matter rather than a specific regulation, but it should still follow the same access-and-traceability principle that regulatory frameworks apply to more sensitive data: limited access, and a documented record of who had it.
References
- DeTora LM, Toroser D, Sykes A, et al. Good Publication Practice (GPP) Guidelines for Company-Sponsored Biomedical Research: 2022 Update. Annals of Internal Medicine. 2022. read 10 October 2026. View on Annals of Internal Medicine
- International Committee of Medical Journal Editors (ICMJE). Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals. read 10 October 2026. View ICMJE Recommendations
- International Society for Medical Publication Professionals (ISMPP). Certified Medical Publication Professional (CMPP) Certification Overview. read 10 October 2026. View on ISMPP
- International Society for Medical Publication Professionals (ISMPP). CMPP Code of Conduct. read 10 October 2026. View ISMPP Code of Conduct
- Committee on Publication Ethics (COPE). Authors' contributions and the involvement of a medical communications company. COPE Case 14-07. read 10 October 2026. View on COPE
- American Medical Writers Association (AMWA). 2024 Compensation Survey: Freelance and Employed Medical Communicators Infographic. read 10 October 2026. View AMWA 2024 Compensation Infographic
- U.S. Department of Health and Human Services, Office for Civil Rights. HIPAA Privacy Rule and Research. read 10 October 2026. View on HHS.gov
- Eaton L. Medical editors issue guidance on ghost writing. BMJ. 2005;330(7498):988. read 10 October 2026. View on The BMJ
- European Medical Writers Association (EMWA). 2022 update to Good Publication Practice Guidelines for Company-Sponsored Biomedical Research. Medical Writing. 2022;31(3). read 10 October 2026. View on EMWA
- International Society for Medical Publication Professionals (ISMPP). Mission and Vision. read 10 October 2026. View on ISMPP
Every source above is a peer-reviewed article, a publisher’s record of one, or a standard issued by the body that owns it. Each carries the date it was last read. Where a standard moves, this article is revised rather than left up with a note.
How to cite this article
Pick your referencing style and copy it. Your university or target journal may vary the punctuation — check its guide if it has one.
Pubrica Academy. (2026, October 10). Confidentiality in the Preparation of Scientific Content: HIPAA Pathways and Commercial Confidentiality. Pubrica. https://pubrica.com/academy/confidentiality-data-security/
Pubrica Academy. “Confidentiality in the Preparation of Scientific Content: HIPAA Pathways and Commercial Confidentiality.” Pubrica, 10 Oct. 2026, pubrica.com/academy/confidentiality-data-security/.
Pubrica Academy (2026) Confidentiality in the Preparation of Scientific Content: HIPAA Pathways and Commercial Confidentiality. Pubrica. Available at: https://pubrica.com/academy/confidentiality-data-security/ (Accessed: 15 October 2026).
Pubrica Academy. “Confidentiality in the Preparation of Scientific Content: HIPAA Pathways and Commercial Confidentiality.” Pubrica. October 10, 2026. https://pubrica.com/academy/confidentiality-data-security/
Pubrica Academy, ‘Confidentiality in the Preparation of Scientific Content: HIPAA Pathways and Commercial Confidentiality’ (Pubrica, 10 October 2026) <https://pubrica.com/academy/confidentiality-data-security/> accessed 15 October 2026.
Pubrica Academy. Confidentiality in the Preparation of Scientific Content: HIPAA Pathways and Commercial Confidentiality. [Internet]. Pubrica; 2026 Oct 10 [cited 2026 Oct 15]. Available from: https://pubrica.com/academy/confidentiality-data-security/
Pubrica Academy, “Confidentiality in the Preparation of Scientific Content: HIPAA Pathways and Commercial Confidentiality,” Pubrica, Oct. 10, 2026. [Online]. Available: https://pubrica.com/academy/confidentiality-data-security/
@misc{/la_slide_deck_confidentiality_data_security_2026,
author = {{Pubrica Academy}},
title = {Confidentiality in the Preparation of Scientific Content: HIPAA Pathways and Commercial Confidentiality},
howpublished = {Pubrica},
year = {2026},
month = {oct},
url = {https://pubrica.com/academy/confidentiality-data-security/},
note = {Accessed: <span data-cite-acc="iso">2026-10-15</span>}
}This article is written to be learned from. Cite it if you are referring to what it says; if you are using the evidence behind it, cite the sources listed above instead.
Confidentiality Pathway Identification Checklist
This tool is intended to identify which confidentiality obligations apply to a scientific content project.
[ ] Determined whether the project touches any patient-level protected health information [ ] If yes, identified the specific HIPAA pathway that applies (waiver, limited data set/DUA, or authorization) [ ] Confirmed any data use agreement includes required safeguard and non-identification terms [ ] Established version control and a documented access/edit trail for unpublished draft content [ ] Disclosed and documented every contributor's access and involvement
Pubrica AcademyWritten and maintained by Pubrica’s subject matter experts. Articles are revised when the underlying standards change, and each article states the date on which it was last reviewed.
How Pubrica can help
Pubrica identifies which specific confidentiality pathway, regulatory or contractual, applies to each scientific content project's actual data, and maintains documented access and disclosure records consistent with HIPAA and GPP2022-aligned accountability standards.